Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial.
J Invest Dermatol. 2020 Dec;140(12):2359-2370.e5. doi: 10.1016/j.jid.2020.03.962. Epub 2020 Apr 18.
J Invest Dermatol. 2020.
PMID: 32311398
Free article.
Clinical Trial.
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study.
Singh RSP, Pradhan V, Roberts ES, Scaramozza M, Kieras E, Gale JD, Peeva E, Vincent MS, Banerjee A, Fensome A, Dowty ME, Winkle P, Tehlirian C.
Singh RSP, et al. Among authors: tehlirian c.
Clin Transl Sci. 2021 Mar;14(2):671-682. doi: 10.1111/cts.12929. Epub 2020 Dec 8.
Clin Transl Sci. 2021.
PMID: 33290616
Free PMC article.
Clinical Trial.
Item in Clipboard
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study.
Tehlirian C, Singh RSP, Pradhan V, Roberts ES, Tarabar S, Peeva E, Vincent MS, Gale JD.
Tehlirian C, et al.
J Am Acad Dermatol. 2022 Aug;87(2):333-342. doi: 10.1016/j.jaad.2022.03.059. Epub 2022 Apr 6.
J Am Acad Dermatol. 2022.
PMID: 35398218
Free article.
Clinical Trial.
Item in Clipboard
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study.
Tehlirian C, Peeva E, Kieras E, Scaramozza M, Roberts ES, Singh RSP, Pradhan V, Banerjee A, Garcet S, Xi L, Gale JD, Vincent MS, Krueger J.
Tehlirian C, et al.
Lancet Rheumatol. 2021 Mar;3(3):e204-e213. doi: 10.1016/S2665-9913(20)30397-0. Epub 2020 Dec 24.
Lancet Rheumatol. 2021.
PMID: 38279383
Item in Clipboard
High-dose cyclophosphamide without stem cell rescue in scleroderma.
Tehlirian CV, Hummers LK, White B, Brodsky RA, Wigley FM.
Tehlirian CV, et al.
Ann Rheum Dis. 2008 Jun;67(6):775-81. doi: 10.1136/ard.2007.077446. Epub 2007 Nov 1.
Ann Rheum Dis. 2008.
PMID: 17974598
Clinical Trial.
Item in Clipboard
Cite
Cite